Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ashtead group revenues slip despite record rental performance

(Sharecast News) - Industrial equipment rental firm Ashtead posted record group rental revenues in the twelve months ended 30 April but said overall revenues had slipped as a result of lower sales of used equipment. Ashtead delivered 4% year-on-year growth in rental revenues to $9.98bn in FY25 but said group revenues were down 1% at $10.79bn as lower used equipment sales and second-hand values resulted in lower gains on sale.

Operating profits slipped 4% to $2.55bn and pre-tax profits fell 5% to $1.99bn, while adjusted underlying earnings were 3% higher at $5.02bn. Earnings per share were also down 5% at $3.465 each, and stated its proposed final dividend of $0.72 would take its FY dividend payout to $1.08, up three cents year-on-year.

Ashtead also delivered "near record free cash flow" of $1.8bn for the year and said, when with "sustained levels of profitability", this had enabled it to invest $2.4bn of capital into its growth runway, alongside its highest ever level of shareholder returns totalling $886.0m across dividends and share buybacks.

Ashtead added that it was on track to move its primary listing to the US during Q126.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.